 SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , May 12, 2022 PRNewswire -- Gracell Biotechnologies Inc. Gracell or the Company, NASDAQ: GRCL, a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the details of three abstracts that it will present at the European Hematology Association 2022 Hybrid Congress EHA2022 Congress, being held from June 9 June 12 in Vienna, Austria. 